Clinical Trials
33 trialsSaltikva for Metastatic Pancreatic Cancer
Salspera LLC
PASS-01
University Health Network, Toronto
Redefining FOLFIORINOX in Older Pancreatic Cancer Patients
Fox Chase Cancer Center
ZSPAC-14
Shanghai Zhongshan Hospital
Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer
Massachusetts General Hospital
Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer
Baylor College of Medicine
Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma
University of Cincinnati
mFOLFIRINOX as Adjuvent Chemotherapy in Treating Chinese Pancreatic Cancer Patients
Sun Yat-sen University
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
Icahn School of Medicine at Mount Sinai
Pancreatic Tumor Cell Vaccine (GVAX), Cyclophosphamide, SBRT, and FOLFIRINOX in Patients With Resected Adenocarcinoma of the Pancreas
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
PANOPTIMOX
Federation Francophone de Cancerologie Digestive
BCC-RAD-13
University of Louisville
FBI-TRAC
King Faisal Specialist Hospital & Research Center
Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")
Medical College of Wisconsin
Induction Chemotherapy Followed by Short Course Radiotherapy in Rectal Cancer
Salah Azaïz Cancer Institute
A Phase II Study of Neoadjuvant FOLFIRINOX
Indiana University
PROTACT
Silenseed Ltd
FOLFIRINOX + RT for Pancreatic Cancer
Massachusetts General Hospital
Systemic Chemotherapy Plus PD-1 for Metastasis ICC
Sun Yat-sen University
FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas
H. Lee Moffitt Cancer Center and Research Institute
FOLFIRINOX
Instituto do Cancer do Estado de São Paulo
A Multicenter Prospective Phase II Study of Modified FOLFIRINOX for 1st Line Treatment for Advanced Urachus Cancer
Asan Medical Center
Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer
Massachusetts General Hospital
Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer
Nagoya University
FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
4CC
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
A Study of Neoadjuvant FOLFIRINOX and FDR-Gemcitabine With Concurrent IMRT in Patients
University of Michigan Rogel Cancer Center
Study of Neoadjuvent Chemotherapy Followed by SBRT in Patients With Resectable and Borderline Resectable Pancreatic Cancer
Indiana University
HAIC of FOLFOX Plus Sorafenib vs HAIC of FOLFIRINOX Plus Sorafenib for Advcanced HCC
Sun Yat-sen University
Oncothermia
Seoul National University Hospital
FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer
UNC Lineberger Comprehensive Cancer Center
FOLFIRINOX
Yale University
Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer
Massachusetts General Hospital